SUMMARY lb determine the effect of blocking central nervous system (CNS) serotonin reuptake in the outcome of acute cerebral infarction (ACI), 49 patients were studied in a double Wind, randomized trial. All patients suffered hemispheric ACI, were seen within 24 hours of onset, and were treated with low dose, subcutaneous beparin to prevent venous thrombosis; 25 received 10 mg. of trazodone hydrochloride intravenously every 12 hours for seven days and 24 were given an identically appearing placebo, l b monitor trazodone effect, indol derivatives were measured in spinal fluid collected before and after treatment in 38 patients. Treatment and placebo patients had similar demographic characteristics, comparable risk factors, and neurologic deBcit at onset. No appreciable difference was seen between treatment and control patients In regard to mtercurrent events, degree of neurologic deficit, time of hospitalization, and mortality. Indol derivatives were consistently higher in the spinal fluid of trazodone patients after treatment, confirming serotonin reuptake blockage; however, this seems to have had no beneficial effect on the outcome of ACI.
NEUROTRANSMITTER DISRUPTION during ischemic stroke has been suggested by elevated levels of norepinephrine and 5-hydroxytryptamine (serotonin) in the cerebrospinal fluid (CSF) of patients with acute cerebral infarction (ACI).' This disruption may be partially responsible for altering the brain blood barrier, facilitating cerebral edema, 2 and for contributing to arteriolar spasm which, in conjunction with clot propagation, perpetuates ischemia. 34 Sustained segmental vasoconstriction may be responsible, in part, for failure of vasomotor reactivity and disruption of cerebral blood flow (CBF) autoregulation during cerebral ischemia. 56 Attempts at alpha and beta adrenergic blockage in patients with cerebral infarction have failed to result in demonstrable clinical improvement. 7 " 9 This could be because the vasoconstriction that occurs with ischemia is not mediated through adrenergic but, rather, through serotoninergic stimulation. 24 If this were the case, blocking serotonin reuptake in the CNS could result in reversal of vasospasm with improvement of collateral circulation, decrease of clot propagation, limitation of infarction size, and minimization of neurologic deficit.
Trazodone
is a piperazine derivative with a wide range of pharmacologic properties, including psychotropic activity. 10 It has an antidepressant action believed to be mediated by its demonstrated property of blocking serotonin reuptake in the CNS."" 16 In a pilot study, Allori, et al 17 reported an open, controlled trial in which patients with ACI were treated with 10 mg. of trazodone intravenously twice a day for seven days in addition to "traditional therapy." These patients were compared to controls treated with traditional therapy only and were found to have lower mortality, milder neurologic deficit, and shorter hospitalization. To try to duplicate these investigators' results, a parallel double blind randomized study was undertaken, the results of which are reported herein.
Methods
Patients of either sex, younger than 80 years, suffering from hemispheric ACI, with no contraindications for anticoagulation, who did not have renal or hepatic insufficiency, and who signed an informed consent were studied. Hemispheric ACI was diagnosed following standard neurologic criteria. 18 After informed consent was obtained, all patients had computed tomography of the head (CT) and lumbar puncture (LP) to rule out hemorrhage. Cerebrospinal fluid analysis was performed and a 10 cc. aliquot was frozen for future determination of serotonin. 19 All patients were then examined by one of the investigators (MRL) and the neurologic deficit rated following the scale shown in table 1. Normal neurologic function received an average score of 10; scores between 9.9 and 8 were defined as mild deficit, 7.9 to 6 as moderate, 5.9 to 4 as marked, and 3.9 or less as severe. All patients were started on low dose (5,000 units) subcutaneous heparin, given every 12 hours. At this point, a box containing 15 one milliliter ampules was assigned to each patient by double blind randomization. The ampules contained either 10 mg. of trazodone hydrochloride in . Treatment was continued for seven days; vital signs and cardiac rhythm were monitored every four hours; blood counts, coagulation parameters, and blood chemistries to monitor hepatic and renal function were done daily. Neurologic examination was repeated and scored on days three, five, seven, and at discharge. Improvement was considered excellent if the score improved by 3.1 or more points, good if by 2.1 to 3, fair if by 0.1 to 2, and poor if no improvement or deterioration occurred. LP was repeated on the last day of treatment; CSF was frozen for future serotonin determination. CT with contrast enhancement was repeated before hospital discharge. The randomization code was computer generated by Mead Johnson Pharmaceutical Laboratories and was broken only after the study was completed and the data tabulated. Results Fifty-three patients (27 males, ages 42 to 80, median 63 years; and 26 females, ages 39 to 80, median 70 years) were studied. Four patients (2 females and 2 males) in whom the code was broken within 24 hours of entrance into the study because of progressive neurologic deterioration were not included in the final tabulation or analysis; two were receiving trazodone and two were controls. Of the 49 patients who completed the trial, 25 (13 males, ages 42 to 78, median 62 years; and 12 females, ages 40 to 80, median 68 years) were treated with trazodone; and 24 (12 males, ages 48 to 80, median 66 years; and 12 females, ages 39 to 70, median 69 years) were controls. Table 2 shows associated conditions found in the treatment and control groups. Table 3 shows the events that occurred during hospitalization, during and after treatment; and table 4 shows neurologic deficit and recovery. A significant difference was observed in CSF concentration of indols, serotonin derivatives, between the treatment and control groups ( fig. 1) . In four patients (3 treatment and 1 control), subcutaneous heparin was disontinued ditions, and degree of neurologic deficit on admission to the trial. Mortality was the same for both groups and no discernible difference was noted in neurologic recovery, degree of deficit at discharge, or hospitalization time between the two groups.
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Elevated serotonin levels in the CSF of patients after ACI 1 are assumed to be due to "leakage" of the neurotransmitter from the ischemic tissue through a damaged brain/CSF barrier. There are no available data to indicate how long it takes for these abnormally high levels to return towards baseline. From the results observed in our control patients, it appears that the period of normalzation of CSF serotonin levels is longer than one week. The observation that serotonin derivative levels were higher after trazodone treatment seems to confirm previous reports that it blocks CNS reuptake of the neurotransmitter." However, this action, which may explain trazodone's antidepressive effect, 1020 ' 21 had no clinical effect in patients after ACI, suggesting that either serotonin plays only a minor role in the complex pathophysiologic events of ACI or that its effects on the ischemic arteries and brain tissue are irreversible. Another possible explanation for the failure of this clinical trial may be found in the multifactorial complexity of the pathophysiology of ACI where correction of one contributing factor, independent of others, has no effect in reverting or even stopping the process.
